The US Food and Drug Administration (FDA) has approved imatinib (Imkeldi) oral solution to treat leukemia and other cancers.
Imatinib is an advanced liquid formulation designed to provide dosing accuracy, according to Shorla Oncology, the manufacturer of the therapy.
Imatinib can help slow or prevent the growth of specific blood cancers, including chronic myeloid leukemia and acute lymphoblastic leukemia, and myelodysplastic syndromes.
“Oral solutions may ensure more precise and consistent dosing, offering a convenient alternative to compounding for patients who have difficulty swallowing or require dosing tailored to body surface area,” Sharon Cunningham, chief executive officer of Shorla, said in a press release from the company.
